Design
Review
No takes yet. Share an insight, caveat, or question.
May inform timing of antiviral vs immunomodulatory strategies; leaves open prospective trials in CVB3 myocarditis.
Maier et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: